Pharmaceutical developer NewBiotics Inc. of San Diego, Calif., has named H. Michael Shepard, PhD, as company president.
Shepard was chief scientific officer and vice president of research at Canji, Inc. before taking the position. He helped develop the p53 gene product for cancer therapy and worked with management to secure financing for the company.
NewBiotics is privately held and is primarily researching breakthrough drugs to treat cancer and infectious disease.
Shepard was a Damon Runyon Fellow at Indiana University and received his doctorate in molecular, cellular, and developmental biology.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.